Related references
Note: Only part of the references are listed.The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
Constantin N. Baxevanis et al.
SEMINARS IN CANCER BIOLOGY (2021)
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Ann Byrne et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Manuela Terranova-Barberio et al.
NATURE COMMUNICATIONS (2020)
The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
Constantin N. Baxevanis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+breast cancer
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2019)
Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
Maria Lucia Hirata Katayama et al.
CELLS (2019)
被撤回的出版物: Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway (Retracted article. See vol. 15, pg. 10735, 2021)
Jianqin Lu et al.
ACS NANO (2018)
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
Samantha Burugu et al.
BREAST CANCER (2017)
Clinical utility of gene-expression signatures in early stage breast cancer
Maryann Kwa et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
Vasiliki Pelekanou et al.
BREAST CANCER RESEARCH (2017)
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
Shicheng Su et al.
CELL RESEARCH (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner et al.
CLINICAL CANCER RESEARCH (2016)
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
Tarek M. A. Abdel-Fatah et al.
LANCET ONCOLOGY (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali et al.
PLOS MEDICINE (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
Francois Bertucci et al.
CANCER LETTERS (2014)
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines
D. Hannani et al.
CELL DEATH AND DIFFERENTIATION (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Christine E. Horak et al.
CLINICAL CANCER RESEARCH (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
The sva package for removing batch effects and other unwanted variation in high-throughput experiments
Jeffrey T. Leek et al.
BIOINFORMATICS (2012)
GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
Tomohiro Miyake et al.
CANCER SCIENCE (2012)
Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2012)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Marieke E. Straver et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
Vlad Popovici et al.
BREAST CANCER RESEARCH (2010)
Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
Fabrice Andre et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression
David G. DeNardo et al.
BREAST CANCER RESEARCH (2007)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
Kenneth R. Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
